Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract. The stomach is the most common site of origin. Management of GISTs changed after the introduction of molecularly targeted therapies. Although the only potentially curative treatment of resectable primary GISTs is surgery, recurrence is common. Patients with primary GISTs at intermediate or high risk of recurrence should receive imatinib postoperatively. Imatinib is also first-line therapy for advanced disease. Cytoreductive surgery might be considered in advanced GIST for patients with stable/responding disease or limited focal progression on tyrosine kinase inhibitor therapy. GIST requires multidisciplinary management.
Original language | English (US) |
---|---|
Pages (from-to) | 437-452 |
Number of pages | 16 |
Journal | Surgical Clinics of North America |
Volume | 97 |
Issue number | 2 |
DOIs | |
State | Published - Apr 1 2017 |
Keywords
- Abdominal tumor
- GIST
- Gastric mass
- Gastrointestinal stromal tumor
- Imatinib
- Sunitinib
- TKIs
- Tyrosine kinase inhibitor
ASJC Scopus subject areas
- Surgery